Related Experiment Videos
PET imaging of cellular proliferation.
David A Mankoff1, Anthony F Shields, Kenneth A Krohn
1Division of Nuclear Medicine, Department of Radiology, University of Washington, 1959 Northeast Pacific Street, Room NN203, Box 356113, Seattle, WA 98195, USA. dam@u.washington.edu
Radiologic Clinics of North America
|February 8, 2005
Summary
Positron Emission Tomography (PET) imaging translates in vitro studies to measure in vivo tumor proliferation. Advances in [18F]-FLT PET imaging show promise for monitoring cancer treatment response.
Area of Science:
- Oncology
- Nuclear Medicine
- Molecular Imaging
Background:
- PET cellular proliferation imaging evolved from in vitro studies of thymidine incorporation into DNA.
- In vitro studies characterized cancer biology and informed the development of imaging agents.
Purpose of the Study:
- To translate in vitro cellular proliferation studies to in vivo measurements using PET imaging.
- To evaluate the role of PET imaging in assessing tumor proliferation and response to therapy.
Main Methods:
- Utilizing PET imaging with thymidine analogues, including [11C]-thymidine and the clinically practical [18F]-FLT.
- Conducting preclinical and early clinical studies to assess the efficacy of PET-labeled thymidine analogues.
Main Results:
- Early clinical studies with [11C]-thymidine showed promising results for PET proliferation imaging.
- Recent progress with [18F]-FLT in patient studies marks the next stage for clinical application.
Conclusions:
- [18F]-FLT PET imaging represents a significant advancement in clinical PET cellular proliferation imaging.
- Further research and clinical trials are essential to establish PET proliferation imaging in cancer patient care for quantitative treatment response monitoring.